Clinical Trials . . . The treatment of inflammatory bowel #174 (IB) is assisted by the regulation of the intestinal bacteriobi.

.Inflammatory bowel disease (IBD) is an idynogenic inflammatory intestinal disease that occurs mainly in the rectum, rectum, and colon. Specific clinical manifestations are diarrhea, abdominal pain, and even blood stools, the course of the disease is long and often repeated. IBD consists of two main types, ulcerative colitis (UC) and Crohn's disease (CD). Ulcerative colitis (UC) is one of the most common forms of inflammatory bowel disease (IBD), mainly continuous inflammation of the mucosa layer and the lower mucous membrane of the colon, the disease usually first affects the rectum and gradually spreads to the whole colon.. The specific cause of IBD is not yet clear, it is known that the inflammatory response caused by abnormal immune system in the intestinal mucosa plays an important role in the onset of IBD, at the same time, environmental, immune, genetic and psychological factors are also important causes of the disease. Currently, the main methods for treating IBD are: bed rest, rehydration of body fluids, and the drug methalazine.(LC-Zhang®, P-8, V9) can effectively improve the intestinal bacteria, with good probiotic effect. Therefore, this trial explores the therapeutic effect ® IBD by studying the clinical effects of the beneficial ® probiotic preparation in the treatment of UC in the same way.trial method 30 UC patients were selected for a 12-week clinical trial using the principle of randomized double blindness. Excluding five volunteers who did not meet the test requirements (including severely ill people with uDAI scores greater than 10, pregnant women, and those who did not have a diagnosis); the remaining 25 mild and moderate patients were randomly divided into probiotic groups (12) and placebo groups (13). The 25 sick volunteers completed the clinical diagnosis, including 10 probiotics and 8 placebo patients who participated in mucous membrane sample collection (intestinal microbial testing, Figure 1). While both groups of patients were treated with methalazine, the probiotic group was given an eugenic ®20 billion CFU (2g) per person per day, while the placebo group was given 2g of the same amount of placebo per day.. Figure 1: The specific process of the trial design, as well as the specific situation of UC patients the results of the trial 1. Clinical diagnosis after 12 weeks of clinical diagnosis showed that the frequency of detox in both groups of patients decreased, the probiotic group in the detox frequency (P<0.01) decreased more significantly than the placebo group, and remained at the level twice daily (Figure 2, a). Indexes such as rectal bleeding in the probiotic group (P-0.035) and UC remission rate (P-0.034) were significantly better than those in the placebo group (Figure 3), where the remission rate in the probiotic group was as high as 91.67 percent, while the remission rate in the placebo group was only 69.23 percent. The UDAI score of the probiotic group was significantly lower than that of the placebo group (P<0.01, Figure 2, bcd).
. Figure 2: Patient detox frequency and specific score details of UCDAIFigure 3: Patient clinical outcome statistics and UCDAI 2. Intestinal mucous membrane microbiobiology and compositional structure analysisα Diversity assessment findings:probiotic group and placebo group mucous membrane microbiobiosis There was a downward trend in both richness and richness during treatment, which was consistent with the previously reported reduction in mucous membrane bacteria during the treatment of UC, but a more significant decrease in microbial richness in the placebo group (P=0.076, Figure 4), indicating that probiotics may help maintain the richness of mucosal bacteriocytos.β diversity analysis found that there was no significant change in the structure of thegroup of mucous membrane microorganisms, but the distance between samples in the placebo group decreased significantly at 12 weeks of treatment (P<0.01), and there was no significant change in the distance between samples in the probiotic group (Figure 4). Probiotics help to maintain the steady state of the entero mucous membrane microbiome without significant changes in the course of treatment.. α
β DiversityFigure 4: Intestinal mucosa microbial diversity (α and β diversity) Details 3. Analysis of changes in the classification of intestinal mucosa microorganismsAt the genus level: at 12 weeks of treatment, Weissella, P<0.05, Ruminoccus There < significant increases in the relative content of beneficial genus P<0.05), mycobacteria genus (Eubacterium, P<0.01), Blautia genus (P<0.05) and Pediococcus (Pediococcus, P<0.05) (Figure 5).at the species level: probiotic therapy significantly increased food Weissella cibaria (P<0.05), fecal tumor gastroococcal (Ruminococcus faeces, P<0.05), fragile bacillus (Bacsinteres fragilis, Intestinal physiological bacteria such as P<0.05) and Eubacterium ramulus (P<0.05), where food Weiss bacteria can promote natural killer cell activity, microcosm is a physiological bacterium that metabolizes flavonoids in the intestines, and fragile bacillus has been shown to fight colitis by interoperability with T cells through membrane polysaccharide A and T cells.
. Figure 5: Details of differences in the microbial composition of the intestinal mucous membranes 4. Spearman Correlation Analysis The Spearman Association Analysis of Intestinal Bacillus and Ulcerative Colitis Activity Index Score (UCDAI) found Weiss genus The rho values of less than 0 for ella, eubacterium, Pediococcus, and some Lactococcus indicate a negative correlation between the levels of these genus and the UDAI score (Figure 6). That is, these beneficial bacteria content increased, UCDAI score decreased. This also shows that probiotics can inhibit the intestinal mucous membrane bacteria in patients with pathogenic bacteria by increasing beneficial bacteria, improving the clinical symptoms of ulcerative colitis. . Figure 6: Spearman Correlation Analysis Details Trial Conclusions Benefit ® (LC-Zhang, P-8, V9) Combined methalazine can significantly alleviate the clinical performance of UC patients and effectively treat IBD, i.e. reduce the number of detoxes, reduce the number of detox bleeding, improve the remission rate and effectively reduce the UDAI score. In terms of intestinal bacterial diversity and microbial species, the benefits are excellent® it can also effectively regulate the patient's intestinal virulology, maintain the stability of the bacterium, improve the content of beneficial bacteria.
.